NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025

Core Viewpoint - NeuroOne Medical Technologies Corporation is actively participating in the Sidoti & Co. Virtual Small-Cap Conference, aiming to enhance its visibility among institutional investors and discuss its recent operational achievements and financial performance [1][2]. Financial Performance - In the third quarter of fiscal year 2025, NeuroOne reported a revenue increase of 105%, reaching $1.7 million compared to the previous year [2]. - The company expanded its gross margin to 53.9% during the same period [2]. Operational Milestones - NeuroOne received FDA 510(k) Clearance for its OneRF® Trigeminal Nerve Ablation System, which is designed to treat facial pain [2]. - The company is funded through at least fiscal year 2026, indicating a stable financial position for ongoing operations and growth initiatives [2]. Company Overview - NeuroOne is focused on developing minimally invasive and high-definition solutions for various neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [3]. - The company is also exploring applications in other areas such as depression, mood disorders, and artificial intelligence [3].